EORTC-55994-GCG

Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.
Trial StatusRecruiting
DatesDate of activation: 19-Mar-02
Data management at EORTCFull
Phase3
Randomized trialYes
TypeNeoadjuvant
Targeted Sample size686
Number of steps1
DrugCisplatin
Study StaffAlessandro Colombo (Study Coordinator) - Ospedale Alessandro Manzoni, Lecco
Stefano Greggi (Study Coordinator) - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli
Gemma Kenter (Study Coordinator) - Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam
Fabio Landoni (Study Coordinator) - Istituto Europeo Di Oncologia, Milano
Corneel Coens (Statistician) - EORTC Headquarters, Brussels
Maarten De Rouck (Data Manager) - EORTC Headquarters, Brussels
Emad Shash (Coordinating Physician) - EORTC Headquarters, Brussels
Nicolas Dif (Project Manager) - EORTC Headquarters, Brussels, nicolas.dif( at )eortc.be, +32 27741043
Ellen Peeters (Project Manager) - EORTC Headquarters, Brussels, ellen.peeters( at )eortc.be, +32 27741082
Type of cancerCervical
Participating GroupsEORTC Gynecological Cancer Group(Coordinating Group)
Centers authorized by EORTC Kaiser Franz Josef Spital (Vienna, Austria) - Inst. 822
Medical University of Graz (Graz, Austria) - Inst. 908
Universitair Ziekenhuis Antwerpen (Edegem, Belgium) - Inst. 117
Centre Hospitalier Regional De La Citadelle (Liege, Belgium) - Inst. 145
U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium) - Inst. 147
Centre Regional Francois Baclesse (Caen, France) - Inst. 206
CHU de Grenoble - La Tronche - H˘pital A. Michallon (Grenoble, France) - Inst. 215
Azienda Ospedaliera CittÓ della Salute e della Scienza di Torino - Azienda Ospedaliera CittÓ della Salute e della Scienza di Torino - Gynecologic Oncology Ospedale S.Anna and University of Turin (Torino, Italy) - Inst. 712
Ospedale Di Circolo E Fondazione Macchi (Varese, Italy) - Inst. 715
Ospedale San Gerardo (Monza, Italy) - Inst. 775
Istituto Europeo Di Oncologia (Milano, Italy) - Inst. 3869
Ospedale Mauriziano Umberto I (Torino, Italy) - Inst. 3902
Hospitais Da Universidade De Coimbra (Coimbra, Portugal) - Inst. 5900
Hospital Universitario San Carlos (Madrid, Spain) - Inst. 366
Erasmus MC Cancer Institute - location Daniel den Hoed (Rotterdam, The Netherlands) - Inst. 302
Radboud University Medical Center Nijmegen (Nijmegen, The Netherlands) - Inst. 304
Universitair Medisch Centrum - Academisch Ziekenhuis (Utrecht, The Netherlands) - Inst. 306
Vrije Universiteit Medisch Centrum (Amsterdam, The Netherlands) - Inst. 308
Leiden University Medical Centre (Leiden, The Netherlands) - Inst. 310
Medisch Spectrum Twente (Enschede, The Netherlands) - Inst. 317
Academisch Medisch Centrum - Universiteit van Amsterdam (Amsterdam, The Netherlands) - Inst. 342
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom) - Inst. 6982
Maidstone & Tunbridge Wells NHS Trust - Maidstone Hospital (Maidstone, United Kingdom) - Inst. 7039
East Kent Hospitals University NHS Foundation Trust - Queen Elizabeth The Queen Mother Hospital (Margate (kent), United Kingdom) - Inst. 7095
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00039338
EudraCT2008-003396-52
Protocol documents in PDF
(requires password)
Study documentation
@
Back to Protocol section